Peter Wostyn
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Peter Wostyn, MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, Belgium[1] and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.[2]
Dr Wostyn developed the unproven glymphatic dysfunction hypothesis which postulates that a dysfunction of the waste clearance system, called the glymphatic system, causes a build-up of toxins within the central nervous system, which he hypothesised precipitates at least some cases of ME/CFS.[3]
Notable studies[edit | edit source]
- 2018, Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?[4]
- 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy[3] - (Abstract)
- 2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction[5]
Talks and interviews[edit | edit source]
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ "Peter Wostyn". LinkedIn. October 22, 2019.
- ↑ "Technology - P&X Medical". px-medical.be. Retrieved October 22, 2019.
- ↑ 3.0 3.1 Wostyn, Peter; De Deyn, Peter Paul (September 2018). "The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy". Medical Hypotheses. 118: 142–145. doi:10.1016/j.mehy.2018.07.007.
- ↑ Wostyn, Peter; De Deyn, Peter Paul (September 2018). "Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?". Medical Hypotheses. 118: 174. doi:10.1016/j.mehy.2018.04.020.
- ↑ Wostyn, Peter (October 4, 2019). "Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction". Medical Hypotheses. 134: 109416. doi:10.1016/j.mehy.2019.109416. ISSN 1532-2777. PMID 31622921.
